Related Experiment Video
Updated: May 26, 2026
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development
Alex Zhavoronkov1,2,3, Qian Wang4, Yujie Liu5
1Insilico Medicine US Inc., Cambridge, MA 02138, USA.
Abstract:
Although aging is increasingly recognized as a key factor in chronic disease management, preclinical drug development rarely incorporates direct assessments of lifespan. To date, no biotechnology company has conducted a full mouse lifespan study for a therapeutic agent prior to human clinical trials, despite widespread chronic use of many approved drugs. This oversight stems from a lack of standardized protocols for the incorporation of mouse lifespan studies, high costs, limited commercial incentives, and regulatory risks associated with long-term data. Here, we present a comprehensive and scalable protocol for conducting mouse longevity studies in the early stages of drug development. Being aware of monetary constraints in the drug discovery process, we propose a basic design for a longevity study on ~250 (176 males and 72 females) genetically heterogeneous mice (UM-HET3) per group, with survival curves as primary endpoint, and propose enhanced study design options only if budget allows. Our framework provides a standardized foundation for integrating longevity assessments into routine drug development, offering the potential to uncover long-term risks or benefits that traditional toxicology studies may overlook. Broad implementation of such protocols could support the development of safer and more effective therapeutics for chronic diseases, while opening new avenues for discovery of substances that could slow down the rate of aging, known as geroprotectors.
Insights
Preclinical drug development often overlooks mouse lifespan studies due to cost and standardization issues. This study introduces a scalable protocol for longevity assessments, crucial for identifying long-term drug effects and aging-related therapeutics.
Area of Science:
- Gerontology
- Pharmacology
- Toxicology
Background:
- Aging is a significant factor in chronic disease, yet preclinical drug development rarely assesses drug impact on lifespan.
- Current drug development lacks standardized mouse lifespan study protocols, hindering the evaluation of long-term therapeutic effects.
- High costs, limited commercial incentives, and regulatory concerns impede the incorporation of longevity studies in drug discovery.
Purpose of the Study:
- To present a comprehensive and scalable protocol for mouse longevity studies in early drug development.
- To establish a standardized framework for integrating lifespan assessments into routine preclinical evaluations.
- To facilitate the discovery of therapeutics that impact aging and chronic disease management.
Main Methods:
- A basic longevity study design using approximately 250 genetically heterogeneous UM-HET3 mice per group (176 males, 72 females).
- Survival curves as the primary endpoint for assessing longevity.
- Proposes enhanced study design options contingent on available budget.
Main Results:
- The proposed protocol offers a standardized foundation for longevity assessments in drug development.
- The framework can uncover long-term risks or benefits missed by traditional toxicology studies.
- Implementation supports the development of safer therapeutics and identifies potential geroprotectors.
Conclusions:
- Standardized mouse longevity studies are essential for comprehensive preclinical drug evaluation.
- This protocol provides a cost-effective and scalable approach to assess drug effects on lifespan.
- Integrating longevity studies can advance the development of chronic disease treatments and anti-aging interventions.
